- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
NVS
Is Tilray Stock a Must-Buy Following New Partnership?
Tilray stock is still very expensive, even after its partnership with Novartis' Sandoz. However, TLRY is in a very tradable range.
Novartis Layoffs 2018: NVS to Cut 2,000 + Jobs
Novartis (NVS) announced that it was laying off 2,000 workers in 2018 as part of a global restructuring, according to a Tuesday announcement.
Novartis Stock Pops on Alcon Spinoff News
Novartis (NVS) stock got a boost today after the company announced plans to spin off its Alcon business sometime next year.
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Novartis AG (ADR) Stock Drops on Q1 Earnings Miss
Novartis (NVS) stock took a hit on Thursday following the release of its earnings report for the first quarter of the year.
A Big Bet on Gene Therapy Is Just What Novartis AG (ADR) Stock Needs
Novartis put its excess cash to good use by broadening its business into the gene therapy market. Competition could prove tough for NVS stock, but Novartis is ready for the challenge ahead.
AveXis Inc Stock Skyrockets on Novartis Deal
AveXis (AVXS) stock was flying high to day following news of am $8.7 billion deal that will have Novartis (NVS) acquiring it.
GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal
GlaxoSmithKline (GSK) stock was up today on news of a $13 billion deal with Novartis (NVS) that it set to close in Summer 2018.
Novartis AG (NVS) a Buy on High-Level Quant Score
Novartis AG (NYSE:NVS) is a member of the 134 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS's market value is $200.3 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for NVS puts it 15 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 109 among the 782 companies in the sector, and number 639 in the nearly 5,000 company Portfolio Grader universe.
Novartis AG (NVS) a Buy on Healthy Quant Score
The current recommendation of Buy for Novartis AG (NYSE:NVS) is derived using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. NVS has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.
3 Stocks to Watch on Friday: Novartis AG (ADR) (NVS), Nutanix Inc (NTNX) and Zumiez Inc. (ZUMZ)
Amazon (AMZN) explores online pharmaceuticals with Novartis AG (NVS), Nutanix (NTNX) and Zumiez (ZUMZ) report on their quarterly earnings.
Novartis AG (NVS) a Buy on Solid Earnings Visibility
Novartis AG (NYSE:NVS) is classified as a constituent of the 133 company Pharmaceuticals GICS industry group, which is a segment of the 781 company GICS Health Care sector. NVS has a market value of $195.5 billion which is in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 23 among the 133 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 166 among the 781 companies in the sector, and number 1,096 in the nearly 5,000 company Portfolio Grader universe.
Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy
The current recommendation of Buy for Novartis AG (NYSE:NVS) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Hold to a Buy in the last week.
Solid Quant Score Metrics Drive Upgrade of Novartis AG (NVS) to Buy
Novartis AG (NYSE:NVS) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Hold to a Buy in the last week.
Anemic Earnings Growth Hurts Novartis AG (NVS) Rating
The current recommendation of Hold for Novartis AG (NYSE:NVS) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for 2 months.
Novartis AG (NVS) Earnings Momentum Hurts Rating
Novartis AG (NYSE:NVS) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS has a market value of $200.9 billion which is in the top decile in its industry group. The ranking for NVS by Portfolio Grader places it 45 among the 133 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 297 among the 782 companies in the sector, and number 2,089 in the nearly 5,000 company Portfolio Grader universe.
Novartis AG (NVS) a Hold on Anemic Industry Group Rank
Currently, Novartis AG (NYSE:NVS) has a Hold using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for 2 months.
